MetaCap

Novavax (NVAX) vs Vor Biopharma (VOR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Vor Biopharma (VOR) has outperformed Novavax (NVAX) over the past year, gaining 157.6% versus a gain of 15.5%. Over five years, VOR leads with a -92.0% price change compared with -96.6% for NVAX. Novavax is the larger company by market cap ($1.23 billion vs $1.18 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NVAX+15.46%VOR+157.58%
+249%+118%-12%
Nov 21, 20251 yearNov 20, 2026
NVAX-96.12%VOR-92.93%
+19%-43%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NVAX versus VOR key metrics
MetricNVAXVOR
Share price$7.47$19.19
Market cap$1.23B$1.18B
1-day change-3.24%+3.62%
YTD return+11.16%+46.71%
1-year return+15.46%+157.58%
5-year return-96.57%-92.00%
P/E ratio (TTM)—0.06
EPS (TTM)$-0.52$300.56
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.12B—
Revenue growth (YoY)+64.69%—
Net income (latest FY)$440.30M$-695.98M
Gross margin93.50%—
Operating margin40.30%—
Net margin39.19%—
52-week high$13.39$26.00
52-week low$6.36$7.21
Distance from 52-week high-44.21%-26.19%
Analyst consensusbuystrong_buy
Avg. price target upside+88.89%+103.23%
Average volume6.67M945.67K
Shares outstanding165.01M61.43M
Employees74976
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • VOR has outperformed NVAX by 142.1 percentage points over the past year.

About Novavax

NVAX stock →

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 749 employees

About Vor Biopharma

VOR stock →

Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 76 employees

NVAX vs VOR FAQ

Which is bigger, Novavax or Vor Biopharma?

Novavax (NVAX) is larger, with a market capitalization of $1.23B compared with $1.18B for Vor Biopharma (VOR).

Which stock has performed better over the past year, NVAX or VOR?

VOR returned +157.58% over the past 12 months, compared with +15.46% for NVAX (price return, excluding dividends). Past performance does not predict future results.

Are Novavax and Vor Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons